Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 52Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 36Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Neoplasms 29Biliary Tract Neoplasms 29Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Head and Neck Neoplasms 19Liver Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 15Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

durvalumab 2alfatide II 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer NSCLC × durvalumab × Clear all
NCT02879617 2024-01-05

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Academic Thoracic Oncology Medical Investigators Consortium

Phase 2 Completed
47 enrolled 34 charts
Thoracic

Non-Small Cell Lung Cancer NSCLC

NCT04667312 2023-10-02

CODAK

AstraZeneca

Completed
115 enrolled
Thoracic

Non-Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡